PROIBS US Distribution Agreement
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Immuron Limited has announced an exclusive distribution agreement for PROIBS® in the United States with Calmino group AB. PROIBS® is a medical device aimed at addressing digestive health issues such as abdominal pain and bloating. The product has been available in European markets for over a decade and is backed by positive user feedback from a usability study. This filing highlights Immuron's strategy to expand its portfolio of digestive health products in the U.S. market.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Immuron
- Immuron Reports FY26 Preliminary Results
- FY26 Results Presentation
- IMC Rare Earths Ltd Announces Closing of $20 Million Initial Public Offering
- Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar
- Immuron FY26 Sales - Four Consecutive Quarters of Growth over Prior Year
Later from Immuron
- Immuron to launch PROIBS® in the United States
- Annual Report for Fiscal Year Ending June 30, 2026 (Form 20-F)
- Immuron FY27 Sales Update
Follow Immuron into a list and get an email when it puts out news.
Follow Immuron